The RK-1 continuous mixing processor from Readco Kurimoto is suited for testing formulations in continuous processing conditions.
Courtesy Readco
Process equipment manufacturer Readco Kurimoto introduced the RK-1 continuous mixing processor, which incorporates the company's proprietary mixing technology in a compact, tabletop unit. The company states that the unit was developed to help product development professionals test new and existing formulations being processed in batches using a continuous process in a controlled, laboratory environment. Scaled down to process 10 lbs/hr, the RK-1 combines heat transfer, mixing, and shear to process multiple powdered, liquid, and viscous ingredients in a single step, while yielding a high quality, homogeneous product at discharge that meets targeted specifications for moisture, texture, color, uniformity, and other criteria.
The novel RK-1 features twin shaft, co-rotating screws with a one-inch diameter set within a closed barrel to promote the intimate contact among wet and dry materials needed to achieve the desired level of mixing, blending, reacting, crystallization, and/or encapsulation. Suitable for use in research and development laboratories for pharmaceuticals and other products, the versatile RK-1 includes touch-screen controls for setup, monitoring, and real-time adjustments. Other available options include a mobile lift table, electric band heater, feed chute, and all-stainless steel construction.
The RK-1 continuous processors are engineered and manufactured in the company's York, PA headquarters. The lab-size processors operate on 220 volts single-phase and are delivered ready to plug in and operate.
Source: Readco
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.